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Abstract
Background: The most common pathologic form of pulmonary fibrosis arises from excessive
deposition of extracellular matrix proteins such as collagen. The 47 kDa heat shock protein 47
(HSP47) is a collagen-specific molecular chaperone that has been shown to play a major role during
the processing and/or secretion of procollagen.
Objectives: To determine whether inhibition of HSP47 could have beneficial effects in mitigating
bleomycin-induced pulmonary fibrosis in rats.
Methods: All experiments were performed with 250–300 g male Wistar rats. Animals were
randomly divided into five experimental groups that were administered: 1) saline alone, 2)
bleomycin alone, 3) antisense HSP47 oligonucleotides alone, 4) bleomycin + antisense HSP47
oligonucleotides, and 5) bleomycin + sense control oligonucleotides. We investigated lung
histopathology and performed immunoblot and immunohistochemistry analyses.
Results: In rats treated with HSP47 antisense oligonucleotides, pulmonary fibrosis was significantly
reduced. In addition, treatment with HSP47 antisense oligonucleotides significantly improved
bleomycin-induced morphological changes. Treatment with HSP47 antisense oligonucleotides
alone did not produce any significant changes to lung morphology. Immunoblot analyses of lung
homogenates confirmed the inhibition of HSP47 protein by antisense oligonucleotides. The bleo +
sense group, however, did not exhibit any improvement in lung pathology compared to bleomycin
alone groups, and also had no effect on HSP47 expression.
Conclusion: These findings suggest that HSP47 antisense oligonucleotide inhibition of HSP47
improves bleomycin-induced pulmonary fibrosis pathology in rats.
Introduction
Pulmonary fibrosis results from various lung injuries and
is a potentially lethal disorder with no effective therapies
currently. Alveolar wall fibrosis with an accumulation of
extracellular matrix molecules, notably collagen, is char-
acteristic [1]. The tendency for progression to end-stage
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pulmonary disease has been correlated to the degree of
extracellular matrix accumulation in the alveolar wall.
Some studies have shown that fibrotic lesions contain the
normal constituents of extracellular matrix, including col-
lagen type IV and V, laminin, and interstitial (type I and
III) collagens [2,3]. However, the underlying molecular
mechanisms responsible for excessive deposition of colla-
gen in fibrotic lesions are not fully understood.
Collagens constitute a family of extracellular proteins that
begin their assembly within the endoplasmic reticulum
lumen and are subsequently secreted from the cell. Type I
to V collagens have been shown to bind to a 47 kDa heat
shock protein (HSP47) [4,5]. Accumulation of HSP47
plays a specific role as a molecular chaperone in the
processing of procollagen molecules [6,7]. HSP47 binds
specifically to collagen and not to other proteins such as
fibronectin or laminin [8].
Under pathologic conditions, HSP47 expression is associ-
ated with collagen biosynthesis in carbon tetrachloride
(CCl4)-induced rat liver fibrosis [9], anti-thymocyte
serum induced glomerulonephritis [10], and a rat rem-
nant kidney model [11]. These findings suggest that
HSP47 may play a crucial role in collagen accumulation.
Antisense phosphorothioate oligonucleotides may be a
potential experimental and therapeutic tool for downreg-
ulating HSP47. Hence, this study aimed to examine
whether HSP47 downregulation can suppress collagen
accumulation in an animal model of bleomycin-induced
pulmonary fibrosis. We also explored whether HSP47-
antisense could be a potential therapeutic application for
pulmonary fibrosis.
Materials and methods
Animals
All protocols conformed to the National Institute of
Health (NIH) guidelines, and animals received care in
compliance with the Principals of Laboratory Animal
Care. Male Wistar rats weighing 250–300 g (Kyudou,
Saga, Japan) were used in all experiments. All animals
were housed with free access to food and water ad libitum.
Experimental protocols
Animals were randomly assigned to one of the five groups
as follows: 1) control group (n = 20) with an intratracheal
administration of 0.9% NaCl solution alone (saline); 2)
bleomycin group (n = 20) with an intratracheal adminis-
tration of bleomycin (Sigma, St. Louis, MO) dissolved in
0.9% NaCl solution (10 unit/kg) (Bleo); 3) antisense
group (n = 20) with an intratracheal administration of
antisense oligonucleotides dissolved in 0.9% NaCl solu-
tion (100 nmol/kg) alone (AS); 4) bleomycin + antisense
group (n = 20) with an intratracheal administration of
antisense oligonucleotides dissolved in 0.9% NaCl solu-
tion (100 nmol/kg) with bleomycin (10 unit/kg)
(Bleo+AS); and 5) bleomycin + sense control group (n =
4) with an intratracheal administration of sense control
oligonucleotides dissolved in 0.9% NaCl solution (100
nmol/kg) with bleomycin (10 unit/kg) (Bleo+S).
All rats were anesthetized with 3% sevofluorane. The tra-
chea was exposed through a midline anterior neck inci-
sion and each agent was injected into the trachea using a
24-gauge needle. At 14 or 28 days after surgery, animals
were sacrificed by clipping the vena cava and transecting
the aorta, followed by an intra-atrial injection of normal
saline. Lung tissue was quickly removed and processed as
described below.
HSP47 antisense and sense control oligonucleotides
Antisense phosphorothioate oligonucleotides (Biognos-
tik GmbH, Germany) were designed as 15 mer analogues
targeted to the first five codons of HSP47. In addition, we
created sense control oligonucleotides that did not act on
HSP47. The sequences of the phosphorothioate oligonu-
cleotides were as follows:
HSP47 antisense: 5'-TACGCGAGAGAGGAA-3'
Sense control: 5'-GTCCCTATACGAACG-3'
These phosphorothioates oligonucleotides were more sta-
ble in vivo and more resistant to intracellular enzymes
when compared with natural phosphodiesters [12].
Histological analysis
Right lower lobe lungs were obtained from animals and
instilled with 10% formalin. Samples were embedded in
paraffin and then cut into 4 μm thickness sections. Sec-
tions were stained with hematoxylin and eosin (H&E),
and the severity of interstitial fibrosis among the groups
was compared using the Ashcroft score [13]. Azan staining
was performed to visualize the collagen fibrils in the tis-
sue.
Hydroxyproline measurement
The total collagen content of the right lung was deter-
mined by hydroxyproline measurement. The hydroxypro-
line content was determined after acid hydrolysis of the
right lung with 12 N HCl in a sealed glass tube (Iwaki,
Tokyo, Japan) at 100°C for 20 hrs [14]. Data are expressed
as milligrams of hydroxyproline per gram of protein in
lungs (mg/g).
Immunohistochemistry analysis of HSP47 protein
The lungs were obtained from each group animals at 14
and 28 days under sevofluran anesthesia. Tissue samples
were fixed immediately in 4% paraformaldehyde at 4°C
overnight, embedded in Optimal Cutting TemperatureRespiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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compound (Sakura Finetechnical Co., Tokyo, Japan), and
cut into 5 μm sections. Endogenous peroxidase activity
was blocked with 0.3% H2O2 and sodium azide (1 mg/
ml) for 10 min. Non-specific protein binding was blocked
by incubation in 10% sheep serum for 10 min. Sections
were then incubated with anti-HSP47 monoclonal anti-
body (1:1000 dilution) overnight at 4°C (Stressgen Bio-
technology, Temecula, CA). Sections were rinsed 3 times
for 5 min each in PBS before incubation with peroxidase-
conjugated anti-mouse IgG (1:1000 dilution) for 1 hrs
and rinsed again with PBS 3 times for 5 min each. Slides
were stained using the biotin avidin peroxidase complex
system from an LSAB2 kit (Dako, Via Real Carpinteria,
CA). After development, slides were counterstained with
Mayer's hematoxylin.
Immunoblot analysis of HSP47 protein
The lungs were obtained from animals after 14 and 28
days after a 10 unit/kg bleomycin or bleomycin + anti-
sense oligonucleotide administration under sevofluran
anesthesia. Blood was cleared by saline perfusion via the
right ventricle and lungs were homogenized with a poly-
tron homogenizer (IKA Labortechnik, Staufen, Germany)
in a T-PER Tissue Protein Extraction Reagent (Pierce,
Rockford, IL). After homogenization, the sample was cen-
trifuged at 10,000 rpm for 5 min. Supernatant was meas-
ured for protein content using the BCA Protein Assay
Regent (Pierce, Rockford, IL) at an absorbance of 562 nm.
Electrophoresis was performed using a discontinuous
Tris-glycine buffer system. Proteins were suspended in
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) buffer (20 mM Tris-HCl, 0.2 M Glycine)
and boiled for 1 min before loading onto 10% gels. Gels
were immediately electrotransferred to polyvinilidene dif-
luoride (PVDF) membranes (Millipore, Bedford, Massa-
chusetts) at 60 V for 3 hrs by means of a wet transfer
system (transfer buffer: 20 mM Tris-HCl, 0.2 M Glycine,
20% MeOH). Membranes were blocked with 5% nonfat
dry milk in TBS/Tween buffer (25 mM Tris-HCl, 0.14 M
NaCl, 2% Tween20) (Bio-Rad Lab., Hercules, CA) over-
night, at 4°C. They were subsequently incubated with pre-
immune serum, diluted 1:1000 in 1% nonfat dry milk, for
1 hr with gentle shaking at room temperature. Secondary
antibody was also diluted in 1% nonfat dry milk (1:1000
dilution) and applied to the membrane for 1 hr at room
temperature. Washing between and after antibody incu-
bation steps was performed three times for 10 min each
with TBS/Tween buffer. Proteins were revealed by
enhanced chemiluminescence (ECL) (Amersham, Buck-
inghamshire, England) and exposed to film (Hyperfilm
ECL; Amersham, Buckinghamshire, England). The film
was scanned and protein band concentrations quantified
by integrated optical density using NIH ImageJ software
(National Institute of Health, U.S.A.).
Statistical analysis
All data were presented as the mean ± standard error of the
mean (S.E.M.). The data was analyzed by a statistical anal-
ysis of variance, a Scheffe's post-hoc test of group pairs for
multiple comparisons, and an unpaired t-test for single
comparisons. A p value < 0.05 was considered to be statis-
tically significant.
Results
Antisense oligonucleotides reduce HSP47 protein
We examined levels of HSP47 protein in whole tissue and
in thin sections of lungs from animals co-treated with ble-
omycin and sense or antisense oligonucleotides. Immu-
nohistochemical analysis of thin sections was performed
to examine the effect of antisense oligonucleotide treat-
ment on bleomycin-induced HSP47 production in vivo.
The Bleo (Fig. 1B) and Bleo+S (Fig. 1E) groups exhibited
strong immunopositivity for HSP47. In contrast, HSP47
staining was significantly reduced in the saline, AS, and
Bleo+AS groups (Fig. 1A, 1C, and 1D). Taken together,
these data indicate that antisense oligonucleotides to
HSP47 inhibit bleomycin-induced HSP47 production.
Next, we utilized immunoblot analysis to examine the
level of HSP47 protein inhibition in the Bleo+AS group as
compared to the Bleo group. Increased levels of HSP47
protein were observed in lung tissue homogenates 2 and
4 weeks after bleomycin injection. Treatment with anti-
sense oligonucleotides, however, inhibited the bleomy-
cin-induced increase of HSP47 at both time points (Fig.
2A and 2B).
Pathology
Lungs were analyzed 4 weeks after treatment with bleomy-
cin alone or bleomycin and antisense oligonucleotides.
The lungs of the Bleo group rats exhibited acute alveolar
injury and pneumonitis which progressed to severe inter-
stitial and intra-alveolar pneumonia and/or fibrosis. In
addition, we observed consolidation of the parenchyma
with loss of the alveolar architecture and increased cell
number. Such lesions varied from focal to diffuse, and col-
lagen was clearly elevated (Fig. 3B). On the other hand,
the Bleo+AS group demonstrated inhibition of pulmo-
nary fibrosis (Fig. 3C). Lung sections from both the saline
(Fig. 3A) and AS groups (Fig. 3D) did not show significant
pulmonary consolidation or fibrosis when sacrificed at 4
weeks. The Bleo+S group demonstrated pulmonary fibro-
sis to the same extent as that of the Bleo group (Fig. 3E).
In a macrograph, the lungs of the Bleo group were firm
and lost significant elasticity (Fig. 4A). However, the lungs
of the Bleo+AS group were almost completely normal
(Fig. 4B). Azan stained sections showed increased connec-
tive tissue in the lungs of the Bleo group (Fig. 5B) com-
pared with that of the Bleo+AS group (Fig. 5C). The saline
and AS groups showed minimal amounts of collagen con-
tent in the lung parenchyma (Fig. 5A and 5D). On theRespiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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Immunohistochemistry for the detection of HSP47 in rat lungs treated with bleomycin with or without antisense HSP47 oligo- nucleotides (ODN) Figure 1
Immunohistochemistry for the detection of HSP47 in rat lungs treated with bleomycin with or without antisense HSP47 oligo-
nucleotides (ODN). (A) A representative lung from a control rat sacrificed at 4 weeks after saline administration; 400×. (B) A 
representative lung from an animal in the Bleo group and sacrificed at 4 weeks; 400×. (C) A representative lung from an animal 
in the Bleo+AS group sacrificed at 4 weeks; 400×. (D) A representative lung from an animal in the antisense group sacrificed at 
4 weeks; 400×. (E) A representative lungs from an animal in the Bleo+S group and sacrificed at 4 weeks; 400×. Arrows indicate 
immunopositivity cells to HSP47.Respiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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(A) Rat lungs treated with bleomycin was lysed and immunoblotted for HSP47 protein Figure 2
(A) Rat lungs treated with bleomycin was lysed and immunoblotted for HSP47 protein. Levels of HSP47 protein at 2 and 4 
weeks were analyzed using Western blotting as described. HSP47 was up-regulated in the Bleo group compared to the 
Bleo+AS group. (B) HSP47 signal intensities were quantified using an image analyzer based on immunoblot density. HSP47 
expression is shown as a percentage of the control. Data is expressed as mean ± SEM. * p < 0.05 vs. control group.Respiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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other hand, the Bleo+S group showed an increase in the
collagen content of lung parenchyma similar to the Bleo
group (Fig. 5E). In addition, Ashcroft scores in the
Bleo+AS group were significantly reduced compared to
the Bleo group (Fig. 6).
Mortality
Approximate thirty percent (30%) of bleo group rats died
within 14 days after the administration of bleomycin,
while all rats receiving with an intratracheal administra-
tion of antisense oligonucleotides with bleomycin sur-
vived. Kaplan-Meier analysis revealed a significantly
shorter time-to-death among the bleo+AS group than the
bleo group. All of the saline and AS group animals were
survived through 28 days.
Hydroxyproline content in lung tissue
Collagen content of bleomycin-injected lungs was
assessed by the hydroxyproline assay. The concentration
of hydroxyproline in the lung tissue 4 weeks after bleomy-
cin injection was significantly higher in the Bleo group
than in the saline control group (Fig. 7). In the Bleo+AS
group, hydroxyproline content was significantly reduced
when compared with that in the Bleo group. There was no
significant difference in hydroxyproline content in the AS
group compared to controls (data not shown).
Discussion
Pulmonary fibrosis is a common consequence, and often
a central feature, of many lung diseases. It is also a highly
lethal disorder. However, the pathogenesis of pulmonary
fibrosis is poorly understood. Recently, various studies
have examined the mechanisms of pulmonary fibrosis
[15,16]. These mechanisms suggest that normal func-
tional lung tissue is replaced with an abnormal accumula-
tion of fibroblasts and collagen. As a result, pulmonary
functions exhibit restricted volumes and capacities,
restricted volumes, and decreased gas exchange [17].
Hence, collagen deposition must be controlled in order to
reverse pulmonary fibrosis and improve the mortality
rate.
HSP47, a 47 kDa collagen-binding glycoprotein, has the
ability to function as a molecular chaperone in the endo-
plasmic reticulum [18]. It is involved in the processing
and transporting of procollagen in the endoplasmic retic-
ulum, and has a molecular chaperone-like function under
stress conditions. The expression of HSP47 is always cor-
related with collagen expression in vitro [19].
It has been found that under pathologic conditions, the
expression of HSP47 is significantly upregulated in con-
junction with collagen expression during the progression
of fibrosis in a rat liver fibrosis model [9] and a rat glomer-
ulonephritis model [10]. It has also been shown that
HSP47 typically colocalized with type I collagen in these
models. These observations suggest that HSP47 might
play an important role in the synthesis, processing, and
secretion of procollagen [19]. In this study, expression of
the HSP47 protein in the lung was increased during bleo-
mycin-induced pulmonary fibrosis. These results suggest
that HSP47 is expressed during pulmonary fibrosis.
HSP47 is the only chaperone protein characterized by spe-
cificity for collagen, and therefore, presents an attractive
target for inhibiting disease progression. Antisense oligo-
nucleotide of HSP47 has been shown to reduce the level
of type I procollagen chains in vitro [20]. In the present
study, we showed that collagen accumulation and disease
progression in an experimental pulmonary fibrosis model
were associated with the level of HSP47 protein expres-
sion. In this model, when rats were treated intratracheally
by direct introduction of antisense oligonucleotides tar-
geting HSP47, fibrotic lesions and collagen expression
were significantly attenuated in line with a decrease in
HSP47 expression. These findings support the theory that
HSP47 plays an important role in the pathogenesis of pul-
monary fibrosis.
Current therapies for pulmonary fibrosis utilizing corti-
costeroids and/or immunosupressants have shown little
benefit [21]. Clinical trials with novel drugs based on
these results are currently being investigated in various
trial phases. However, to date, there are no effective ther-
apies for treating pulmonary fibrosis [22]. Tran et al. [23]
reported positive effects of adenovirus-mediated transfer
of the bacterial bleomycin resistance gene in a mice model
of bleomycin-induced pulmonary fibrosis. However, this
approach is limited to bleomycin-induced pneumopathy,
and is not useful for other types of interstitial pulmonary
fibrosis. While various in vivo gene transfer techniques
have successfully delivered genes into the lungs and
treated pulmonary fibrosis [24-27], these methods are too
cumbersome for standard use in fibrosis therapy.
Recently, a novel variation in gene delivery was intro-
duced wherein oligonucleotide phosphorothioates were
shown to be stable in most tissues. These analogues of oli-
gonucleotides were more resistant to nuclease than their
unmodified counterparts, and were therefore expected to
exhibit longer activities [28]. Without using any specific
vectors, the oligonucleotides in the experiment were
incorporated into alveolar cells. This approach presents a
more promising method of therapy. Consequently,
molecular therapy through the delivery of antisense oligo-
nucleotides has posed a possible new treatment for pul-
monary fibrosis [29].
Our study examined whether treatment with antisense
oligonucleotides to HSP47 could reduce collagen deposits
in a bleomycin model of pulmonary fibrosis. Our findingsRespiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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H&E staining of bleomycin-treated rat lungs with and without antisense HSP47 ODN Figure 3
H&E staining of bleomycin-treated rat lungs with and without antisense HSP47 ODN. (A) Lungs from the saline group; 40× (B) 
Lungs from the Bleo group at 4 weeks following bleomycin treatment exhibit diffuse consolidation of parenchyma with loss of 
alveolar architecture and increased cell number; 40×. (C) Lungs from the Bleo+AS group at 4 weeks post-injection demon-
strates improvement of lesions compared to the Bleo alone group; 40×. (D) Lungs from the AS alone group at 4 weeks post-
injection show no significant pulmonary consolidation or fibrosis; 40×. (E) Lungs from the Bleo+S group at 4 weeks post-injec-
tion exhibit diffuse consolidation of parenchyma with loss of alveolar architecture and increased cell number; 40×.Respiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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demonstrated that the introduction of antisense oligonu-
cleotides against HSP47 effectively decreases HSP47 pro-
tein levels and reduces fibrotic lesions. In addition,
without using any specific vectors, the oligonucleotides in
the present experiment were incorporated or phagocy-
tized into activated alveolar macrophages. Our previous
study showed that in vivo collagen accumulation was sup-
pressed by inhibition of its molecular chaperone in
fibrotic diseases [30]. Taken together, these results suggest
that antisense inhibition of the substrate-specific molecu-
lar chaperone HSP47 may provide a promising new
approach to molecular therapy for pulmonary fibrosis. As
a caveat, we simultaneously administered HSP47 anti-
sense oligonucleotides and bleomycin to the rat lung in
this study. We have no evidence as to the effect of delayed
administration of antisense HSP47 oligonucleotides to a
bleomycin affected lung, which requires further study.
Conclusion
In this study, we demonstrate that antisense HSP47 oligo-
nucleotides inhibited pulmonary fibrosis in bleomycin
treated rat lungs. Analysis of HSP47 protein expression
revealed a central role of HSP47 in the progression of ble-
omycin-induced pulmonary fibrosis. In fact, HSP47 pro-
tein may actively participate in the pathophysiology of
pulmonary fibrosis. Consequently, HSP47 antisense oli-
gonucleotides may be useful for treating various fibrosis.
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Macrograph of lungs treated with bleomycin alone (A) or bleomycin + antisense HSP47 ODN (B) and sacrificed 28 days later Figure 4
Macrograph of lungs treated with bleomycin alone (A) or bleomycin + antisense HSP47 ODN (B) and sacrificed 28 days later. 
(A) Lungs from a Bleo only treated animal exhibit fibrosis and loss of alveolar architecture. (B) Lungs from a Bleo+AS treated 
animal exhibit normal morphology and no signs of fibrosis.Respiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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Azan staining of lung tissue from each group Figure 5
Azan staining of lung tissue from each group. (A) Azan staining of the saline group shows minimal collagen content in the lung 
parenchyma; 100×. (B) Azan staining of the Bleo group shows an increase in the collagen content of lung parenchyma; 100×. 
(C) Azan staining the Bleo+AS group shows a reduction in collagen fibrils compared to the saline and Bleo groups; 100×. (D) 
Azan staining the AS group shows minimal collagen in the lung parenchyma; 100×. (E) Azan staining of the Bleo+S group shows 
an increase in the collagen content of lung parenchyma, comparable to the Bleo group; 100×.Respiratory Research 2007, 8:37 http://respiratory-research.com/content/8/1/37
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